CannMed marks 10 years with focus on cannabis regulation, medicine and veterans

By AI, Created 10:24 AM UTC, May 20, 2026, /AGP/ – CannMed 26 will bring scientists, physicians, regulators and industry leaders to Lake Tahoe from June 15-18, 2026, as federal rescheduling, hemp policy and veteran PTSD research approach key turning points. The summit is marking its 10th anniversary with a program aimed at helping attendees navigate the industry’s shifting legal and scientific landscape.

Why it matters: - CannMed 26 arrives as federal rescheduling, hemp policy and veteran PTSD research are all at a tipping point. - The summit is built to help cannabis, hemp, supplement and nutraceutical operators understand the regulatory changes that could reshape the market. - The event is also positioning cannabis science and medicine as a response to uncertainty across federal oversight, clinical use and product safety.

What happened: - The CannMed Innovation & Collaboration Summit will meet in Lake Tahoe from June 15-18, 2026. - CannMed 26 is celebrating the summit’s 10th anniversary. - The event will gather cannabis scientists, physicians, regulators and industry leaders. - The 2026 summit is centered on legislative and regulatory changes affecting the industry.

The details: - Featured faculty include Ethan Russo, Staci Gruber, Bonni Goldstein and Sue Sisley. - Russo is a former GW Pharmaceuticals Phase III advisor on Sativex and Epidiolex and author of the entourage effect paper cited hundreds of times in peer-reviewed literature. - Gruber leads the MIND Program at McLean Hospital and Harvard Medical School and has published more than 133 papers. - Goldstein has treated more than 20,000 patients, including more than 2,000 children, and wrote Cannabis is Medicine. - Sisley is the principal investigator on the only FDA-approved randomized controlled trial of smoked cannabis for veteran PTSD. - Other featured participants include Dustin Sulak, Steph Sherer, Kevin McKernan and Benjamin Miller. - The speaker list also includes researchers from Advanced Nutrients, USP, The Salk Institute, Cornell University, Cronos Group, the University of British Columbia, bioMerieux, Curaleaf, Organigram and the Veterans Alliance for Holistic Alternatives. - Program sessions include One-Plant Policy: Hemp, Cannabis & the Road to Unified Federal Oversight. - That session will examine whether hemp and cannabis intended for human consumption should follow the same safety standards regardless of THC. - Featured speakers for that session include Steph Sherer, Dustin Sulak, USP’s Amy Cadwallader and Jordan Wellington of Strategy 64. - The Medical Practicum is a full-day educational program for clinicians and professionals. - The practicum will cover endocannabinoid system fundamentals and evidence-based cannabinoid therapeutics for chronic pain, neurologic disorders, autoimmune conditions and more. - Goldstein, Sulak and Russo will lead the Medical Practicum. - Another session, Psychedelics, Cannabis & Veterans: PTSD, TBI, and the Future of Trauma-Informed Care, will examine clinical evidence, policy pathways and access for veterans. - Sisley will join combat veterans and advocates in that session. - The session will be timed against congressional hearings and the DEA’s increased psilocybin production quotas. - The Federal Regulatory Playbook: FDA, FSMA, USDA & USP will focus on what federal cannabis regulation could look like in practice. - Ben Miller of The Acheson Group will moderate that session. - The program also includes sessions on cultivation science, cannabis emulsions and precision delivery, microbial safety and minor cannabinoids. - CannMed says the 2026 event will be its most comprehensive scientific program to date. - Registration is open at CannMed event registration. - Sponsorship packages and discounted hotel accommodations at the Hyatt Regency Lake Tahoe are available while inventory lasts. - CannMed launched in 2016 through Medicinal Genomics Corporation, with the first conferences held at Harvard Medical School. - The summit has convened thousands of researchers, clinicians, cultivators, regulators and investors over the past decade. - Medicinal Genomics Corporation describes itself as a molecular science company focused on genomics-based pathogen detection, genetic testing and microbiome analysis for cannabis, hemp, dietary supplements, nutraceuticals, botanicals and food products.

Between the lines: - CannMed is leaning into policy uncertainty as a driver of attendance and relevance. - The speaker lineup mixes clinical credibility, regulatory expertise and industry operators, signaling a push to be both a scientific forum and a policy-working meeting. - The emphasis on veterans, psilocybin and federal standards suggests the summit is trying to stay ahead of the next phase of cannabis and adjacent plant-based therapies.

What’s next: - Attendees will use the June summit to track possible shifts in federal oversight and clinical research. - The event’s outcomes could include new research partnerships, clinical initiatives and safety-standard discussions. - Sponsorship and hotel availability will remain limited as the event approaches.